QQQ   303.02 (-0.19%)
AAPL   152.00 (+0.18%)
MSFT   260.87 (+1.60%)
META   186.20 (+0.08%)
GOOGL   103.32 (+0.41%)
AMZN   98.52 (-3.58%)
TSLA   192.71 (-1.05%)
NVDA   212.76 (+0.89%)
NIO   10.73 (-1.83%)
BABA   104.90 (-0.52%)
AMD   83.38 (-0.36%)
T   19.40 (-0.92%)
F   13.06 (-0.61%)
MU   60.28 (+0.50%)
CGC   2.88 (-2.37%)
GE   81.43 (-1.12%)
DIS   109.46 (-0.37%)
AMC   6.43 (-5.44%)
PFE   43.76 (+0.00%)
PYPL   81.52 (-0.98%)
NFLX   357.00 (-1.24%)
QQQ   303.02 (-0.19%)
AAPL   152.00 (+0.18%)
MSFT   260.87 (+1.60%)
META   186.20 (+0.08%)
GOOGL   103.32 (+0.41%)
AMZN   98.52 (-3.58%)
TSLA   192.71 (-1.05%)
NVDA   212.76 (+0.89%)
NIO   10.73 (-1.83%)
BABA   104.90 (-0.52%)
AMD   83.38 (-0.36%)
T   19.40 (-0.92%)
F   13.06 (-0.61%)
MU   60.28 (+0.50%)
CGC   2.88 (-2.37%)
GE   81.43 (-1.12%)
DIS   109.46 (-0.37%)
AMC   6.43 (-5.44%)
PFE   43.76 (+0.00%)
PYPL   81.52 (-0.98%)
NFLX   357.00 (-1.24%)
QQQ   303.02 (-0.19%)
AAPL   152.00 (+0.18%)
MSFT   260.87 (+1.60%)
META   186.20 (+0.08%)
GOOGL   103.32 (+0.41%)
AMZN   98.52 (-3.58%)
TSLA   192.71 (-1.05%)
NVDA   212.76 (+0.89%)
NIO   10.73 (-1.83%)
BABA   104.90 (-0.52%)
AMD   83.38 (-0.36%)
T   19.40 (-0.92%)
F   13.06 (-0.61%)
MU   60.28 (+0.50%)
CGC   2.88 (-2.37%)
GE   81.43 (-1.12%)
DIS   109.46 (-0.37%)
AMC   6.43 (-5.44%)
PFE   43.76 (+0.00%)
PYPL   81.52 (-0.98%)
NFLX   357.00 (-1.24%)
QQQ   303.02 (-0.19%)
AAPL   152.00 (+0.18%)
MSFT   260.87 (+1.60%)
META   186.20 (+0.08%)
GOOGL   103.32 (+0.41%)
AMZN   98.52 (-3.58%)
TSLA   192.71 (-1.05%)
NVDA   212.76 (+0.89%)
NIO   10.73 (-1.83%)
BABA   104.90 (-0.52%)
AMD   83.38 (-0.36%)
T   19.40 (-0.92%)
F   13.06 (-0.61%)
MU   60.28 (+0.50%)
CGC   2.88 (-2.37%)
GE   81.43 (-1.12%)
DIS   109.46 (-0.37%)
AMC   6.43 (-5.44%)
PFE   43.76 (+0.00%)
PYPL   81.52 (-0.98%)
NFLX   357.00 (-1.24%)
NASDAQ:EYPT

EyePoint Pharmaceuticals - EYPT Stock Forecast, Price & News

$4.52
-0.07 (-1.53%)
(As of 02/7/2023 10:13 AM ET)
Add
Compare
Today's Range
$4.52
$4.70
50-Day Range
$2.37
$5.04
52-Week Range
$2.19
$14.41
Volume
10,558 shs
Average Volume
330,118 shs
Market Capitalization
$154.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00

EyePoint Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
622.7% Upside
$32.67 Price Target
Short Interest
Bearish
8.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.15) to ($2.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

729th out of 1,027 stocks

Analytical Instruments Industry

20th out of 27 stocks

EYPT stock logo

About EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Stock News Headlines

EyePoint Shareholder Notice
EyePoint Shareholder Action Reminder
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
EyePoint To Build 40K Sq. Ft. Facility To Make EYP-1901, YUTIQ
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
EYPT EyePoint Pharmaceuticals, Inc.
EyePoint Investor Alert
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT)
See More Headlines
Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Company Calendar

Last Earnings
11/03/2021
Today
2/07/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYPT
Employees
122
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$32.67
High Stock Price Forecast
$52.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+408.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-58,420,000.00
Net Margins
-186.02%
Pretax Margin
-186.02%

Debt

Sales & Book Value

Annual Sales
$35.31 million
Book Value
$5.44 per share

Miscellaneous

Free Float
30,034,000
Market Cap
$154.04 million
Optionable
Optionable
Beta
0.99

Social Links


Key Executives

  • Nancy Sue Lurker
    Chief Executive Officer & Director
  • Jay S. Duker
    President & Chief Operating Officer
  • George O. Elston
    CFO & Head-Corporate Development
  • Dario A. Paggiarino
    Chief Medical Officer & Senior Vice President
  • Said Saim
    Chief Technology Officer













EYPT Stock - Frequently Asked Questions

Should I buy or sell EyePoint Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings
or view top-rated stocks.

What is EyePoint Pharmaceuticals' stock price forecast for 2023?

4 analysts have issued 1 year price targets for EyePoint Pharmaceuticals' shares. Their EYPT share price forecasts range from $21.00 to $52.00. On average, they expect the company's stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 611.7% from the stock's current price.
View analysts price targets for EYPT
or view top-rated stocks among Wall Street analysts.

How have EYPT shares performed in 2023?

EyePoint Pharmaceuticals' stock was trading at $3.50 at the start of the year. Since then, EYPT stock has increased by 31.1% and is now trading at $4.59.
View the best growth stocks for 2023 here
.

When is EyePoint Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our EYPT earnings forecast
.

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.11. The company had revenue of $9.06 million for the quarter, compared to analysts' expectations of $9.60 million. EyePoint Pharmaceuticals had a negative net margin of 186.02% and a negative trailing twelve-month return on equity of 48.00%. During the same quarter in the prior year, the business earned ($0.30) earnings per share.

When did EyePoint Pharmaceuticals' stock split?

EyePoint Pharmaceuticals's stock reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of EyePoint Pharmaceuticals own?
What is EyePoint Pharmaceuticals' stock symbol?

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Who are EyePoint Pharmaceuticals' major shareholders?

EyePoint Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.59%), Legato Capital Management LLC (0.22%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include George Elston and Nancy Lurker.
View institutional ownership trends
.

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EyePoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $4.59.

How much money does EyePoint Pharmaceuticals make?

EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $156.43 million and generates $35.31 million in revenue each year. The company earns $-58,420,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis.

How many employees does EyePoint Pharmaceuticals have?

The company employs 122 workers across the globe.

How can I contact EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050.

This page (NASDAQ:EYPT) was last updated on 2/7/2023 by MarketBeat.com Staff